Rivaroxaban delivery and reversal at a venous flow rate

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 12, 2012, Pages 2877-2883

  Haynes, Laura M ^a   Orfeo, Thomas ^a   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

factor Xa inhibitors; flow; prothrombinase; rivaroxaban; venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; PHOSPHOLIPID; PROTHROMBIN; RIVAROXABAN;

ARTICLE; BLOOD FLOW VELOCITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBUS; VEIN BLOOD FLOW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD FLOW VELOCITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR V; FACTOR VA; FACTOR XA; HUMANS; MODELS, BIOLOGICAL; MORPHOLINES; REGIONAL BLOOD FLOW; RISK FACTORS; THIOPHENES; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 84870059539     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300053     Document Type: Article

References (33)

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012;141:e44S-e88.S.
2. Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012:141:e24S-e43.S.
3. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI. Population pharmacokinetics and pharmacodynamics of once and twicedaily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-461.
4. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol. 2006;46:981-990. (Pubitemid 44215062)
5. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, Steinke W. Pharmacokinetics of BAY 597939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica. 2005;35:891-910. (Pubitemid 41759174)
6. Orfeo T, Butenas S, BrummelZiedins KE, Gissel M, Mann KG. Anticoagulation by factor Xa inhibitors. J Thromb Haemost. 2010;8:1745-1753.
7. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
8. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30:376-381.
9. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 597939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521. (Pubitemid 41632877)
10. Haynes LM, Dubief YC, Orfeo T, Mann KG. Dilutional control of prothrombin activation at physiologically relevant shear rates. Biophys J. 2011;100:765-773.
11. Haynes LM, Dubief YC, Mann KG. Membrane binding events in the initiation and propagation phases of tissue factorinitiated zymogen activation under flow. J Biol Chem. 2012;287:5225-5234.
12. Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2006;26:1729-1737. (Pubitemid 44305325)
13. Runyon MK, Kastrup CJ, JohnsonKerner BL, Ha TG, Ismagilov RF. Effects of shear rate on propagation of blood clotting determined using microfluidics and numerical simulations. J Am Chem Soc. 2008;130:3458-3464. (Pubitemid 351456047)
14. Okorie UM, Denney WS, Chatterjee MS, Neeves KB, Diamond SL. Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow. Blood. 2008;111:3507-3513.
15. Neeves KB, Illing DA, Diamond SL. Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow. Biophys J. 2010;98:1344-1352.
16. Burghaus R, Coboeken K, Gaub T, Kuepfer L, Sensse A, Siegmund HU, Weiss W, Mueck W, Lippert J. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS ONE. 2011;6:e17626.
17. Higgins DL, Mann KG. The interaction of bovine factor V and factor Vderived peptides with phospholipid vesicles. J Biol Chem. 1983;258:6503-6508. (Pubitemid 13106824)
18. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA. 1981;78:162-166. (Pubitemid 11131257)
19. Bajaj SP, Mann KG. Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsinactivated factor X. J Biol Chem. 1973;248:7729-7741.
20. Butenas S, DiLorenzo ME, Mann KG. Ultrasensitive fluorogenic substrates for serine proteases. Thromb Haemost. 1997;78:1193-1201. (Pubitemid 27464585)
21. Butenas S, Orfeo T, Lawson JH, Mann KG. Aminonaphthalenesulfonamides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes. Biochemistry. 1992;31:5399-5411.
22. Kalb E, Frey S, Tamm LK. Formation of supported planar bilayers by fusion of vesicles to supported phospholipid monolayers. Biochim Biophys Acta. 1992;1103:307-316.
23. Tamm LK, McConnell HM. Supported phospholipid bilayers. Biophys J. 1985;47:105-113.
24. Wagner NM, Dressel T, Schäfer K, Konstantinides S. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wildtype and apolipoprotein Edeficient mice. Thromb Res. January 24, 2012. doi: 10.1016/j.thromres.2012.01.002. http://www.sciencedirect.com/science/article/ pii/S0049384812000060. Accessed October 8, 2012.
25. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26:27-32.
26. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007;45:335-344. (Pubitemid 46895052)
27. Orfeo T, Butenas S, BrummelZiedins KE, Mann KG. The tissue factor requirement in blood coagulation. J Biol Chem. 2005;280:42887-42896. (Pubitemid 43049251)
28. Orfeo T, BrummelZiedins KE, Gissel M, Butenas S, Mann KG. The nature of the stable blood clot procoagulant activities. J Biol Chem. 2008;283:9776-9786.
29. Hérault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect factor Xa inhibitors on free and clotbound prothrombinase. J Pharmacol Exp Ther. 1997;283:16-22. (Pubitemid 27438941)
30. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of wholeblood clots. J Clin Invest. 1993;91:1877-1883. (Pubitemid 23141454)
31. Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther. 2001;296:567-572. (Pubitemid 32112487)
32. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem. 1979;254:10952-10962. (Pubitemid 10163282)
33. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin. 2006;22:471-481.